Hensoldt Second Quarter 2025 Earnings: EPS Misses Expectations
Key Financial Results
Revenue: €549.0m (up 5.6% from 2Q 2024).
Net loss: €12.0m (loss widened by 20% from 2Q 2024).
€0.10 loss per share (further deteriorated from €0.081 loss in 2Q 2024).
Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Hensoldt Earnings Insights
Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Aerospace & Defense industry in Germany.
Performance of the German Aerospace & Defense industry.
The company's shares are down 5.5% from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Hensoldt (at least 1 which is a bit concerning), and understanding them should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Raffles Medical Group First Half 2025 Earnings: EPS: S$0.017 (vs S$0.017 in 1H 2024)
Raffles Medical Group (SGX:BSL) First Half 2025 Results Key Financial Results Revenue: S$378.4m (up 3.5% from 1H 2024). Net income: S$32.1m (up 4.8% from 1H 2024). Profit margin: 8.5% (up from 8.4% in 1H 2024). The increase in margin was driven by higher revenue. EPS: S$0.017 (in line with 1H 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period Raffles Medical Group Earnings Insights Looking ahead, revenue is forecast to grow 2.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare industry in Asia. Performance of the market in Singapore. The company's shares are down 4.8% from a week ago. Risk Analysis Before you take the next step you should know about the 1 warning sign for Raffles Medical Group that we have uncovered. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
36 minutes ago
- Yahoo
Oversea-Chinese Banking Corporation Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Oversea-Chinese Banking Corporation Limited (SGX:O39) shareholders are probably feeling a little disappointed, since its shares fell 2.3% to S$16.79 in the week after its latest second-quarter results. Revenues were S$3.5b, approximately in line with whatthe analysts expected, although statutory earnings per share (EPS) crushed expectations, coming in at S$1.60, an impressive 298% ahead of estimates. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Following the latest results, Oversea-Chinese Banking's 17 analysts are now forecasting revenues of S$14.3b in 2025. This would be a reasonable 4.1% improvement in revenue compared to the last 12 months. Statutory earnings per share are expected to dip 2.5% to S$1.58 in the same period. In the lead-up to this report, the analysts had been modelling revenues of S$14.4b and earnings per share (EPS) of S$1.61 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results. Check out our latest analysis for Oversea-Chinese Banking It will come as no surprise then, to learn that the consensus price target is largely unchanged at S$17.61. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Oversea-Chinese Banking, with the most bullish analyst valuing it at S$20.00 and the most bearish at S$14.40 per share. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable. These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Oversea-Chinese Banking's past performance and to peers in the same industry. It's pretty clear that there is an expectation that Oversea-Chinese Banking's revenue growth will slow down substantially, with revenues to the end of 2025 expected to display 8.3% growth on an annualised basis. This is compared to a historical growth rate of 11% over the past five years. Compare this to the 497 other companies in this industry with analyst coverage, which are forecast to grow their revenue at 7.2% per year. Factoring in the forecast slowdown in growth, it looks like Oversea-Chinese Banking is forecast to grow at about the same rate as the wider industry. The Bottom Line The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. The consensus price target held steady at S$17.61, with the latest estimates not enough to have an impact on their price targets. With that in mind, we wouldn't be too quick to come to a conclusion on Oversea-Chinese Banking. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Oversea-Chinese Banking analysts - going out to 2027, and you can see them free on our platform here. We don't want to rain on the parade too much, but we did also find 1 warning sign for Oversea-Chinese Banking that you need to be mindful of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Glenfiddich and the Balvenie's Parent Company Reports a Nearly 30% Profit Drop in 2024
It seems that tough times continues to hound the spirits industry, and scotch whisky is one category that is feeling the pain. Late last week, the family-owned company William Grant & Sons (owner of major whisky distilleries Glenfiddich and the Balvenie, as well as Milagro Tequila and Sailor Jerry Rum) reported a significant decrease in profits by nearly 30 percent in 2024. It remains to be seen how this year will play out, but that's a lot of ground to make up. According to a recent article in The Herald, WGS, which is owned by the billionaire Grant family, reported that its profits dropped by about a third in the year ending in December of 2024, and revenue was down by 6.5 percent. 'In a year marked by industry-wide challenges, the decline in revenue compared to 2023 is in line with market trends, including the continuation of significant destocking,' said a rep for the company in a statement. 'Despite these significant headwinds, William Grant & Sons maintained its commitment to quality and innovation. This was demonstrated by the announcement of Glenfiddich's multi-year partnership with the Aston Martin Formula One team in November 2024, bringing together two brands renowned for their heritage, innovation, and pursuit of excellence.' More from Robb Report A Brand-New Pebble Beach Compound Overlooking Spyglass Hill's 11th Fairway Lists for $10.9 Million One of America's Biggest Whiskey Distilleries Has Seen Its Sales Plummet Ex-Google CEO Eric Schmidt Just Dropped $110 Million on Aaron Spelling's Former L.A. Mansion Despite these challenges, Glenfiddich and the Balvenie remain in the list of top five best-selling single malts (rounded out by the Macallan, the Glenlivet, and Glenmorangie). And WGS completed the purchase of Naked Malt and the Famous Grouse this month; the latter is the best-selling blended scotch in the U.K., so presumably that will help sales figures. On the other hand, the company decided to partially pause production at its Tullamore D.E.W. distillery in Ireland this past spring, part of an ongoing trend in the whisky industry. (The company said production will resume this summer.) Of course, we are only halfway through 2025, so it remains to be seen whether these losses will continue or the course will be reversed, although the recent negotiation between the Trump administration and the E.U. resulting in a 15 percent tariff likely won't help. In the U.K., politicians are pressing him to ease the current 10 percent tariff on scotch that has been levied against the industry to the tune of about £4 million per week, according to the Independent. The situation remains fluid, but we will report back with any significant updates. Best of Robb Report Why a Heritage Turkey Is the Best Thanksgiving Bird—and How to Get One 9 Stellar West Coast Pinot Noirs to Drink Right Now The 10 Best Wines to Pair With Steak, From Cabernet to Malbec Click here to read the full article. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
